Next Article in Journal
Escherichia hermannii Infections in Humans: A Systematic Review
Next Article in Special Issue
A Call for Systems Epidemiology to Tackle the Complexity of Schistosomiasis, Its Control, and Its Elimination
Previous Article in Journal / Special Issue
Use of Geospatial Surveillance and Response Systems for Vector-Borne Diseases in the Elimination Phase
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
TropicalMed
Volume 4
Issue 1
10.3390/tropicalmed4010016
tropicalmed-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Trop. Med. Infect. Dis. 2018, 3(4), 121.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Tendler, M., et al. Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine. Trop. Med. Infect. Dis. 2018, 3, 121

by
Miriam Tendler
*,
Marília S. Almeida
,
Monica M. Vilar
,
Patrícia M. Pinto
and
Gabriel Limaverde-Sousa
FIOCRUZ—Instituto Oswaldo Cruz, Laboratório de Esquistossomose Experimental, Av. Brasil, 4365, Manguinhos, Rio de Janeiro 21045-900, Brazil
*
Author to whom correspondence should be addressed.
Trop. Med. Infect. Dis. 2019, 4(1), 16; https://doi.org/10.3390/tropicalmed4010016
Submission received: 16 January 2019 / Accepted: 18 January 2019 / Published: 19 January 2019
(This article belongs to the Special Issue Prospects for Schistosomiasis Elimination)
Versions Notes
The authors wish to make the following correction to this paper [1]:
Where it reads:
“In order to have a consistent, stable and defined final product for clinical human use, the Sm14 antigen was formulated with the synthetic adjuvant glucopyranosyl lipid A (GLA-SE), a clinically-approved molecule already used in a number of commercially-available human vaccines.”
It should read:
“In order to have a consistent, stable and defined final product for clinical human use, the Sm14 antigen was formulated with the synthetic adjuvant glucopyranosyl lipid A (GLA-SE), an adjuvant successfully tested in clinical trials with different human vaccine candidates.”
The authors would like to apologize for any inconvenience caused to the readers by this change.

Reference

  1. Tendler, M.; Almeida, M.S.; Vilar, M.M.; Pinto, P.M.; Limaverde-Sousa, G. Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine. Trop. Med. Infect. Dis. 2018, 3, 121. [Google Scholar] [CrossRef] [PubMed]

Share and Cite

MDPI and ACS Style

Tendler, M.; Almeida, M.S.; Vilar, M.M.; Pinto, P.M.; Limaverde-Sousa, G. Correction: Tendler, M., et al. Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine. Trop. Med. Infect. Dis. 2018, 3, 121. Trop. Med. Infect. Dis. 2019, 4, 16. https://doi.org/10.3390/tropicalmed4010016

AMA Style

Tendler M, Almeida MS, Vilar MM, Pinto PM, Limaverde-Sousa G. Correction: Tendler, M., et al. Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine. Trop. Med. Infect. Dis. 2018, 3, 121. Tropical Medicine and Infectious Disease. 2019; 4(1):16. https://doi.org/10.3390/tropicalmed4010016

Chicago/Turabian Style

Tendler, Miriam, Marília S. Almeida, Monica M. Vilar, Patrícia M. Pinto, and Gabriel Limaverde-Sousa. 2019. "Correction: Tendler, M., et al. Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine. Trop. Med. Infect. Dis. 2018, 3, 121" Tropical Medicine and Infectious Disease 4, no. 1: 16. https://doi.org/10.3390/tropicalmed4010016

Article Metrics

Back to TopTop